As the utility of ctDNA testing to guide targeted molecular therapy has been widely assessed through NSCLC patients with EGFR sensitizing mutations, we will use this as an example to reflect on how these tests were incorporated into clinical practice. Here, EGFR is linked to non-small cell lung carcinoma.